AbbVie
ABBV
2,243 hedge funds and large institutions have $94.8B invested in AbbVie in 2019 Q4 according to their latest regulatory filings, with 328 funds opening new positions, 830 increasing their positions, 831 reducing their positions, and 58 closing their positions.
466% more first-time investments, than exits
New positions opened: 328 | Existing positions closed: 58
55% more funds holding in top 10
Funds holding in top 10: 73 → 113 (+40)
18% more capital invested
Capital invested by funds: $80.2B → $94.8B (+$14.6B)
12% more funds holding
Funds holding: 2,002 → 2,243 (+241)
0.75% more ownership
Funds ownership: 71.67% → 72.42% (+0.75%)
0% less repeat investments, than reductions
Existing positions increased: 830 | Existing positions reduced: 831
19% less call options, than puts
Call options by funds: $1.91B | Put options by funds: $2.37B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$690M |
| 2 |
JP Morgan Chase
New York
|
+$376M |
| 3 |
Renaissance Technologies
New York
|
+$373M |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$287M |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$273M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$1.16B |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$576M |
| 3 |
BlackRock
New York
|
-$253M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$194M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$134M |
ABBV Hedge Fund Activity: Q4 2019 in Review
2,243 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2019, worth a combined $94.8B — up 18% from $80.2B a quarter earlier.
Buyers outnumbered sellers: 328 funds opened new ABBV positions and 58 closed out — a net gain of 270 holders — while 830 added to existing stakes and 831 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $690M. The largest seller was Capital Research Global Investors, cutting an estimated $1.16B.
- 2,243 institutional investors held AbbVie (ABBV) as of Q4 2019, up from 2,002 in Q3 2019.
- Funds reported $94.8B of AbbVie stock for Q4 2019, up 18% quarter-over-quarter.
- 328 funds opened new AbbVie positions in Q4 2019 and 58 closed out, a net change of +270 holders.
- The largest AbbVie buyer in Q4 2019 was T. Rowe Price Associates, an estimated $690M added.
- The largest AbbVie seller in Q4 2019 was Capital Research Global Investors, an estimated $1.16B sold.
Based on aggregated 13F filings for Q4 2019.